rosiglitazone has been researched along with Hyperglycemia, Postprandial in 74 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 38 (51.35) | 29.6817 |
2010's | 34 (45.95) | 24.3611 |
2020's | 2 (2.70) | 2.80 |
Authors | Studies |
---|---|
Burris, TP; Combs, DW; Demarest, KT; Rybczynski, PJ; Turchi, I; Xu, JZ; Yang, M; Zeck, RE | 1 |
Berger, JP; Bergman, JP; Desai, RC; Doebber, TW; Gratale, DF; Han, W; Heck, JV; Leung, K; MacNaul, KL; Metzger, EJ; Moller, DE; Sahoo, SP | 1 |
Henke, BR | 1 |
Araki, K; Arita, T; Furukawa, A; Hayashi, S; Kuroha, M; Matsui, Y; Ohsumi, J; Satoh, S; Wakabayashi, K | 1 |
Abdallah, AE; Eissa, IH; ElSohly, MA; Ibrahim, MK; Metwaly, AM; Radwan, MM | 1 |
Huang, T; Song, J; Wei, X; Zhang, M; Zhao, J; Zhao, Y; Zhou, Y | 1 |
Alawi, LF; Chodavarapu, H; El-Amouri, SS; Elased, KM; Emberesh, SE; Fadnavis, R; Owuor, BA | 1 |
Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
Yin, Q; Zhuang, Y | 1 |
Rimbach, G; Schrader, E; Wein, S; Wolffram, S | 1 |
Chodavarapu, H; Elased, KM; Grobe, N; Madhu, M; Salem, ES; Somineni, HK | 1 |
Huang, HG; Lin, YH; Lou, M; Sun, JZ; Wen, SQ; Zhang, FH | 1 |
Chang, Y; Hu, S; Li, Z; Wang, J; Wang, Y; Xue, C | 1 |
Allen, SR; Cawyer, CR; Horvat, D; Jones, RO; Kuehl, TJ; Leonard, D; Uddin, MN; Zawieja, DC | 1 |
Agarwal, S; Bilezikian, JP; Fitzpatrick, LA; Manavalan, JS; McMahon, DJ; Nino, A; Rubin, MR | 1 |
Berggren-Söderlund, M; Feng, Y; Luo, G; Mu, Q; Nilsson-Ehle, P; Qin, L; Shi, Y; Xu, N; Zhang, J; Zhang, X; Zheng, L | 1 |
Chen, Y; Han, H; Liu, B; Wang, J; Xu, F; Xue, M; Yuan, Q | 1 |
Chen, M; Feng, T; Han, X; Li, N; Li, Y; Liu, C; Liu, P; Si, S; Wang, X; Xu, Y; Zhu, N | 1 |
Beeram, MR; Kohl-Thomas, BM; Kuehl, TJ; Lin, S; Nguyen, T; Pantho, AF; Uddin, MN; Zawieja, DC | 1 |
Cander, S; Ersoy, C; Guclu, M; Oz Gul, O; Ozkaya, G; Sarandol, E; Unal, O | 1 |
Han, JS; Park, MH | 1 |
Kavimani, S; Kesavanarayanan, KS; Prathiba, D; Priya, RJ; Selvakkumar, C | 1 |
Cho, DH; Jo, I; Kim, SA; Park, JH; Park, JY; Seo, J; Song, KH | 1 |
Chao, CY; Hsu, CC; Kuo, YH; Li, PY; Tang, FY; Yin, MC | 1 |
Afroze, SH; Allen, S; Cawyer, C; Drever, N; Jones, R; Kuehl, T; Uddin, MN; Zawieja, DC | 1 |
Cho, YM; Choi, HH; Chung, SS; Kim, JH; Lee, HK; Lee, KW; Park, HS; Park, KS | 1 |
Gaikwad, AB; Pathan, AR; Ramarao, P; Viswanad, B | 1 |
Chen, Y; Jimbu, YM; Lu, YL; Yang, H; Ye, TT; Zhao, JB | 1 |
Choi, MS; Jeon, SM; Jung, UJ; Kang, YJ; Lee, MK; Song, H; Yeo, J | 1 |
Lebovitz, HE | 1 |
Scheen, AJ | 2 |
Bosch, J; Dagenais, GR; Diaz, R; Gerstein, HC; Lonn, EM; Mohan, V; Sheridan, P; Smith, S; Yusuf, S | 1 |
Gore, MO; McGuire, DK | 1 |
McGill, JB | 1 |
Jiang, JD; Kong, WJ; Pan, HN; Song, DQ; Wang, SK; Wang, YM; Wang, ZZ; Wei, J; Wu, JD; Xue, R; Zhang, H; Zhao, W; Zhou, ZX | 1 |
Chajut, A; Cooper, A; Lee, S; Leizerman, I; Molero, JC; Walder, K | 1 |
Bi, F; Liu, JN; Su, Y; Tang, Y; Zhang, J | 1 |
Limor, R; Oron, Y; Rosenthal, T; Stern, N; Younis, F; Zangen, S | 1 |
DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C | 1 |
Anand, S; Boyko, EJ; Gerstein, HC; Mohan, V; Shaw, JE; Sheridan, P; Yusuf, S | 1 |
Bae, MH; Chae, YN; Choi, HH; Choi, SH; Hur, Y; Kim, E; Kim, JG; Kim, MK; Lim, JI; Moon, HS; Park, CS; Park, YH; Shin, CY; Son, MH | 1 |
Fernandes, G; Halade, GV; Lindsey, ML; Williams, PJ | 1 |
Rabøl, R | 1 |
Elased, KM; Lucot, JB; Sharma, AN | 1 |
Hart, CM; Lu, X; Sutliff, RL; Williams, CR | 1 |
Feng, Y; Ruan, KF; Wang, LY; Wang, S; Wang, Y; Xu, DS | 1 |
Chan, YC; Hong, LZ; Hung, SW; Tsai, CI; Tseng, CJ; Wang, JY; Wang, MF | 1 |
Albertz, J; Duan, W; Guo, Z; Jin, J; Peng, Q; Ross, CA; Rudow, G; Troncoso, JC | 1 |
Brewer, B; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Lambert, G; Matsusue, K; Reitman, ML; Ward, JM; Yim, SH | 1 |
Viberti, GC | 1 |
Badiwala, MV; Fedak, PW; Li, RK; Li, SH; Mickle, DA; Verma, S; Wang, CH; Weisel, RD | 1 |
Barringhaus, KG; Chen, M; Czarnik, AC; Hesselbacher, S; Ley, K; Nadler, J; Phillips, JW; Sanders, JM; Sarembock, IJ; Yang, Z | 1 |
Evans, M; Rees, A; Roberts, AW; Thomas, A | 1 |
Benelli, C; Duplus, E; Forest, C; Fouque, F; Reis, AF; Velho, G | 1 |
Agrawal, A; Bennett, SM; Elasha, H; Heise, M; Jones, NP; Walker, M; Wilding, JP | 1 |
Gavrilova, O; Haluzik, M; Kim, H; LeRoith, D; Pajvani, UB; Portas, J; Scherer, PE; Sun, H; Yakar, S | 1 |
Chen, X; Cryan, E; Demarest, KT; Osborne, MC; Rybczynski, PJ; Tang, Y; Xu, J; Yang, M; Zeck, R; Zhou, L | 1 |
Alonso, M; Vidal, A | 1 |
Chow, WS; Hoo, RL; Kraegen, EW; Lam, KS; Sweeney, G; Tso, AW; Wang, Y; Wat, NM; Xu, A; Xu, JY; Zhang, J | 1 |
Gaikwad, AB; Ramarao, P; Viswanad, B | 1 |
Andres, J; Bähr, V; Bobbert, T; Diederich, S; Mai, K; Maser-Gluth, C; Möhlig, M; Pfeiffer, AF; Spranger, J | 1 |
Goldberg, RB | 1 |
Roussel, R | 1 |
Abram, SR; Carter, C; Dearman, J; Hester, RL; Xiang, L | 1 |
Kapoor, JR | 1 |
Arch, JR; Buckingham, RE; Cai, XJ; Lister, CA; Pickavance, L; Wilding, J; Williams, G; Wilson, S | 1 |
Stiefelhagen, P | 1 |
Buckingham, RE; Lister, CA; Smith, SA; Toseland, CD | 1 |
Boehm, M; Crombie, DL; Davies, PJ; Depre, C; Heyman, RA; Leibowitz, MD; Liu, S; Nagy, L; Singh Ahuja, H; Tontonoz, P | 1 |
Akanuma, Y; Ezaki, O; Fukayama, M; Hori, W; Ide, T; Itai, A; Kadowaki, T; Kagechika, H; Kamon, J; Kato, S; Kimura, S; Komeda, K; Kubota, N; Miki, H; Motojima, K; Murakami, K; Nagai, R; Shudo, K; Terauchi, Y; Tobe, K; Tsuboyama-Kasaoka, N; Tsuchida, A; Waki, H; Yamauchi, N; Yamauchi, T | 1 |
Lund, S; Pedersen, O; Vestergaard, H | 1 |
Ardecky, RJ; Bean, JS; Bensch, WR; Bilakovics, JM; Broderick, CL; Brooks, DA; Brozinick, JT; Dana, SL; Etgen, GJ; Johnson, WT; Kauffman, RF; Liu, S; McCarthy, JR; Misener, EA; Montrose, CR; Ogilvie, KM; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, JS | 1 |
8 review(s) available for rosiglitazone and Hyperglycemia, Postprandial
Article | Year |
---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Quinolines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2009 |
Selecting among ADA/EASD tier 1 and tier 2 treatment options.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glyburide; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Practice Guidelines as Topic; Prognosis; Risk Assessment; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Treatment Outcome | 2009 |
Mitochondrial function in skeletal muscle in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Electron Transport; Humans; Hyperglycemia; Hypoglycemic Agents; Life Style; Mitochondria; Muscle Fibers, Skeletal; Muscle, Skeletal; Obesity; Oxidative Stress; Oxygen Consumption; Rosiglitazone; Saponins; Thiazolidinediones | 2011 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2003 |
The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?
Topics: Adult; Aged; Carotid Arteries; Clinical Trials as Topic; Diabetes Mellitus; Disease Progression; Female; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Ramipril; Rosiglitazone; Thiazolidinediones | 2007 |
10 trial(s) available for rosiglitazone and Hyperglycemia, Postprandial
Article | Year |
---|---|
Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Remodeling; Cell Lineage; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Osteoclasts; Postmenopause; Rosiglitazone; Stem Cells; Thiazolidinediones | 2014 |
Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM.
Topics: Adipokines; Adiponectin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Fibrinogen; Humans; Hyperglycemia; Hypoglycemic Agents; Inflammation; Insulin; Insulin Secretion; Leptin; Male; Middle Aged; Prognosis; Prospective Studies; Resistin; Rosiglitazone; Thiazolidinediones; Young Adult | 2015 |
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Fasting; Female; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Ramipril; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Tunica Intima; Ultrasonography | 2009 |
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
Topics: Aged; Berberine; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liver Diseases; Male; Metformin; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Insulin; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2010 |
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Venoms; Weight Gain | 2010 |
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hyperglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Ramipril; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Glucose Clamp Technique; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Postprandial Period; Rosiglitazone; Thiazolidinediones | 2004 |
[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Ramipril; Rosiglitazone; Thiazolidinediones | 2006 |
Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenocorticotropic Hormone; Blood Glucose; Enzyme Activation; Gene Expression Regulation, Enzymologic; Glucose Tolerance Test; Humans; Hydrocortisone; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Middle Aged; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones | 2007 |
[Three studies in type 2 diabetes: DREAM the wash-out results].
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hyperglycemia; Hypoglycemic Agents; Ramipril; Rosiglitazone; Thiazolidinediones | 2007 |
56 other study(ies) available for rosiglitazone and Hyperglycemia, Postprandial
Article | Year |
---|---|
Benzoxazinones as PPARgamma agonists. part 1: SAR of three aromatic regions.
Topics: Adaptor Protein Complex 2; Adipocytes; Animals; Area Under Curve; Biological Availability; Gene Expression; Half-Life; Humans; Hyperglycemia; In Vitro Techniques; Indicators and Reagents; Luciferases; Mice; Microsomes, Liver; Oxazines; Rats; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Subcellular Fractions; Transcription Factors | 2003 |
5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcription Factors | 2003 |
Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives.
Topics: Animals; Benzofurans; Crystallography, X-Ray; Diabetes Mellitus; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Models, Molecular; PPAR gamma | 2010 |
Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.
Topics: Animals; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Design; Hyperglycemia; Male; Models, Molecular; Molecular Structure; PPAR gamma; Quinoxalines; Rats; Rats, Wistar; Streptozocin; Structure-Activity Relationship; Sulfonylurea Receptors | 2017 |
Hyperglycemia Aggravates Blood-Brain Barrier Disruption Following Diffuse Axonal Injury by Increasing the Levels of Inflammatory Mediators through the PPARγ/Caveolin-1/TLR4 Pathway.
Topics: Animals; Blood-Brain Barrier; Caveolin 1; Diffuse Axonal Injury; Endothelial Cells; Glucose; Humans; Hyperglycemia; Inflammation Mediators; Interleukin-6; Oxygen; PPAR gamma; Rats; Rosiglitazone; Tight Junction Proteins; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2023 |
Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice.
Topics: Animals; Diabetic Nephropathies; Down-Regulation; Hyperglycemia; Hypoglycemic Agents; Kidney; Male; Mice; Neprilysin; Rosiglitazone | 2020 |
Peroxisome proliferator-activated receptor γ agonists attenuate hyperglycaemia-induced hyaluronan secretion in vascular smooth muscle cells by inhibiting PKCβ2.
Topics: Gene Expression Regulation; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Hyperglycemia; Muscle, Smooth, Vascular; Pioglitazone; PPAR gamma; Protein Kinase C beta; Protein Kinase Inhibitors; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2013 |
Oral green tea catechins transiently lower plasma glucose concentrations in female db/db mice.
Topics: Adiponectin; Adipose Tissue; Animals; Anti-Inflammatory Agents; Blood Glucose; Camellia sinensis; Catechin; Diabetes Mellitus, Type 2; Dietary Supplements; Female; Flavonoids; Hyperglycemia; Hypoglycemic Agents; Inflammation; Intercellular Adhesion Molecule-1; Mice; Mice, Knockout; Mice, Obese; Obesity; Phytotherapy; Plant Extracts; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Gain | 2013 |
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion.
Topics: ADAM Proteins; ADAM17 Protein; Albuminuria; Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucose Tolerance Test; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Kidney Diseases; Male; Membrane Proteins; Mice; Peptidyl-Dipeptidase A; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2013 |
Rosiglitazone attenuates hyperglycemia-enhanced hemorrhagic transformation after transient focal ischemia in rats.
Topics: Animals; Blood Glucose; Collagen Type IV; Glucose Transporter Type 1; Hemoglobins; Hyperglycemia; Hypoglycemic Agents; Immunohistochemistry; Infarction, Middle Cerebral Artery; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Nervous System Diseases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2013 |
Fucosylated chondroitin sulfate from sea cucumber in combination with rosiglitazone improved glucose metabolism in the liver of the insulin-resistant mice.
Topics: Animals; Blood Glucose; Body Weight; Chondroitin Sulfates; Diet, High-Fat; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Glucose Tolerance Test; Glucose-6-Phosphatase; Glycogen; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hexokinase; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyruvate Kinase; Receptor, Insulin; Rosiglitazone; Sea Cucumbers; Signal Transduction; Thiazolidinediones | 2013 |
Hyperglycemia impairs cytotrophoblast function via stress signaling.
Topics: Antigens, CD; Diabetes, Gestational; Endoglin; Enzyme-Linked Immunosorbent Assay; Female; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Imidazoles; Interleukin-6; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Placenta Growth Factor; Plasminogen Activator Inhibitor 1; Polymerase Chain Reaction; PPAR gamma; Pregnancy; Pregnancy Proteins; Pyridines; Receptors, Cell Surface; Rosiglitazone; Signal Transduction; Thiazolidinediones; Trophoblasts; Urokinase-Type Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2014 |
Rosiglitazone enhances apolipoprotein M (Apom) expression in rat's liver.
Topics: Animals; Apolipoproteins; Apolipoproteins M; Gene Expression Regulation; Hyperglycemia; Hypoglycemic Agents; Lipocalins; Liver; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2014 |
Acute Hepatic Insulin Resistance Contributes to Hyperglycemia in Rats Following Myocardial Infarction.
Topics: Animals; Blood Glucose; Gluconeogenesis; Hyperglycemia; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Myocardial Infarction; Rats; Receptor, Insulin; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2015 |
Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Benzamides; Cell Differentiation; Cyclin-Dependent Kinase 5; Diabetes Mellitus, Experimental; Disease Models, Animal; Hyperglycemia; Indoles; Mice; Osteoblasts; Osteogenesis; Phosphorylation; PPAR gamma; Protein Binding; Rosiglitazone; Thiazolidinediones | 2015 |
Hyperglycemia down-regulates cGMP-dependent protein kinase I expression in first trimester cytotrophoblast cells.
Topics: Cell Line; Cyclic GMP; Cyclic GMP-Dependent Protein Kinase Type I; Down-Regulation; Female; Glucose; Guanylate Cyclase; Humans; Hyperglycemia; Imidazoles; Pregnancy; Pregnancy Trimester, First; Pyridines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Soluble Guanylyl Cyclase; Thiazolidinediones; Trophoblasts | 2015 |
Padina arborescens Ameliorates Hyperglycemia and Dyslipidemia in C57BL/KsJ-db/db Mice, a Model of Type 2 Diabetes Mellitus.
Topics: Adiponectin; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Dyslipidemias; Fasting; Glucose Tolerance Test; Glycated Hemoglobin; Glycogen; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Phaeophyceae; Rosiglitazone; Thiazolidinediones | 2015 |
Herbal formulation, DIA-2 and Rosiglitazone ameliorates hyperglycemia and hepatic steatosis in type 2 diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diet, High-Fat; Fatty Liver; Hyperglycemia; Hypoglycemic Agents; Liver Diseases; Plant Extracts; Random Allocation; Rats; Rosiglitazone; Thiazolidinediones | 2015 |
Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNFα-stimulated endothelial cells by inhibiting IKKβ expression.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Cattle; Cell Adhesion; Diabetes Mellitus; Endothelial Cells; Humans; Hyperglycemia; I-kappa B Kinase; Inflammation; Monocytes; PPAR gamma; Rosiglitazone; Telmisartan; Thiazolidinediones; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
Protective Effects of Red Guava on Inflammation and Oxidative Stress in Streptozotocin-Induced Diabetic Mice.
Topics: Animals; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Experimental; Hyperglycemia; Inflammation; Insulin; Insulin Resistance; Interleukin-10; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Oxidative Stress; Plant Extracts; Psidium; Rosiglitazone; Streptozocin; Taiwan; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2015 |
Attenuation of hyperglycemia-induced apoptotic signaling and anti-angiogenic milieu in cultured cytotrophoblast cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 9; Cells, Cultured; Cyclooxygenase 2; Enzyme Inhibitors; Female; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Imidazoles; Interleukin-6; p38 Mitogen-Activated Protein Kinases; Placenta Growth Factor; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rosiglitazone; Signal Transduction; Thiazolidinediones; Trophoblasts; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Activation of PPARgamma negatively regulates O-GlcNAcylation of Sp1.
Topics: Acetylglucosamine; Acylation; Animals; Cell Line; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Protein Processing, Post-Translational; Rosiglitazone; Sp1 Transcription Factor; Thiazolidinediones; Transcription, Genetic; Zinc Fingers | 2008 |
Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats.
Topics: Animals; Behavior, Animal; Blood Glucose; Cognition; Dietary Fats; Disease Models, Animal; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Maze Learning; Memory; Motor Activity; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
The effects of rosiglitazione on renal artery endothelium in diabetic rats.
Topics: Animals; Blood Glucose; Cell Adhesion; Diabetes Mellitus, Experimental; Endothelium, Vascular; Female; Hyperglycemia; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Reference Values; Renal Artery; Rosiglitazone; Thiazolidinediones | 2008 |
Potential hypoglycemic effect of an ethanol extract of Gynostemma pentaphyllum in C57BL/KsJ-db/db mice.
Topics: Animals; Blood Glucose; Dose-Response Relationship, Drug; Glucokinase; Glucose Tolerance Test; Glucose-6-Phosphatase; Gynostemma; Hyperglycemia; Hypoglycemic Agents; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Liver; Male; Mice; Mice, Inbred C57BL; Pancreas; Phytotherapy; Plant Extracts; Plant Leaves; Rosiglitazone; Thiazolidinediones | 2008 |
Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
Topics: Aged; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Rosiglitazone: to be or not to be?
Topics: Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Practice Guidelines as Topic; Rosiglitazone; Thiazolidinediones | 2009 |
Effects of rosiglitazone on intramyocellular lipid accumulation in Psammomys obesus.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Dietary Carbohydrates; Gerbillinae; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin; Intracellular Space; Lipids; Male; Rosiglitazone; Thiazolidinediones | 2010 |
The novel function of nesfatin-1: anti-hyperglycemia.
Topics: Anilides; Animals; Appetite Depressants; Blood Glucose; Calcium-Binding Proteins; DNA-Binding Proteins; Eating; Hyperglycemia; Hypolipidemic Agents; Insulin; Mice; Mice, Mutant Strains; Nerve Tissue Proteins; Nucleobindins; Peptide Hormones; Pyrazoles; Pyrimidines; Receptors, Leptin; Rosiglitazone; Thiazolidinediones | 2010 |
Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hyperglycemia; Hypertension; Insulin; Insulin Resistance; Leptin; PPAR gamma; Rats; Rats, Inbred SHR; Rosiglitazone; Telmisartan; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Gain | 2010 |
PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cells, Cultured; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Phenylpropionates; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Water-Electrolyte Balance | 2011 |
Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice.
Topics: Aging; Animals; Collagen; Corn Oil; Diet; Female; Fish Oils; Heart; Hyperglycemia; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Inflammation; Insulin Resistance; Mice; Mice, Inbred C57BL; Rosiglitazone; Thiazolidinediones; Ultrasonography | 2011 |
Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice.
Topics: Animals; Antidepressive Agents; Blood Glucose; Depressive Disorder; Diabetes Mellitus, Type 2; Emotions; Glucose Tolerance Test; Hyperglycemia; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Motor Activity; Psychotic Disorders; Rosiglitazone; Swimming; Thiazolidinediones | 2012 |
Rosiglitazone attenuates NF-κB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells.
Topics: Cells, Cultured; Endothelial Cells; Humans; Hyperglycemia; NADPH Oxidase 4; NADPH Oxidases; NF-kappa B; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Up-Regulation; Vasodilator Agents | 2012 |
MDG-1, a polysaccharide from Ophiopogon japonicus exerts hypoglycemic effects through the PI3K/Akt pathway in a diabetic KKAy mouse model.
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experimental; Female; Glucose Tolerance Test; Glucose Transporter Type 4; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Mice, Inbred C57BL; Ophiopogon; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Plant Roots; Polysaccharides; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides | 2012 |
Modulation of baroreflex function by rosiglitazone in prediabetic hyperglycemic rats.
Topics: Animals; Baroreflex; Blood Pressure; Hyperglycemia; Hypoglycemic Agents; Prediabetic State; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2012 |
Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Topics: Adenosine Triphosphate; Anilides; Animals; Brain; Brain-Derived Neurotrophic Factor; Cell Line; Disease Models, Animal; Gene Expression Regulation; Glutamates; Humans; Huntingtin Protein; Huntington Disease; Hyperglycemia; Intracellular Signaling Peptides and Proteins; L-Lactate Dehydrogenase; Male; Mice; Mice, Transgenic; Movement Disorders; Nerve Tissue Proteins; Neurons; Neuropeptides; Neuroprotective Agents; Orexins; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; RNA, Messenger; Rosiglitazone; Sirtuins; Thiazolidinediones; Trans-Activators; Transcription Factors; Transfection; Trinucleotide Repeat Expansion | 2013 |
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.
Topics: Animals; Blood Glucose; Fatty Acids, Nonesterified; Fatty Liver; Hyperglycemia; Insulin Resistance; Leptin; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Leptin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone.
Topics: Arteriosclerosis; C-Reactive Protein; Endothelium, Vascular; Humans; Hyperglycemia; Hypoglycemic Agents; Rosiglitazone; Saphenous Vein; Thiazolidinediones | 2003 |
Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
Topics: Animals; Blood Glucose; Carotid Arteries; Carotid Artery Injuries; Cells, Cultured; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Female; Homozygote; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Rosiglitazone; Thiazoles; Thiazolidinediones; Tunica Intima | 2003 |
Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2 diabetes.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Enhancer Elements, Genetic; Gene Expression Regulation, Enzymologic; Gene Frequency; Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating); Humans; Hyperglycemia; Organ Specificity; Phosphoenolpyruvate Carboxykinase (GTP); Polymorphism, Genetic; PPAR gamma; Promoter Regions, Genetic; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2003 |
Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Transgenic; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2004 |
Pharmacological profile of a novel, non-TZD PPARgamma agonist.
Topics: Adipocytes; Animals; Benzoxazines; Blood Glucose; Diabetes Mellitus, Experimental; Female; Gene Expression Regulation; Glycated Hemoglobin; Hepatocytes; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Lipid Metabolism; Male; Mice; Mice, Obese; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Triglycerides | 2005 |
[Dermatomyositis, lipodystrophy and insulin resistance].
Topics: Child; Dermatomyositis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Lipodystrophy; Male; Rosiglitazone; Thiazolidinediones | 2006 |
Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.
Topics: Acute-Phase Proteins; Adult; Age Factors; Aged; Animals; Biomarkers; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hyperglycemia; Inflammation; Insulin Resistance; Lipocalin-2; Lipocalins; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Middle Aged; Obesity; Oncogene Proteins; Polymerase Chain Reaction; PPAR gamma; Proto-Oncogene Proteins; Rosiglitazone; Sex Factors; Thiazolidinediones | 2007 |
PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; PPAR gamma; Prediabetic State; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Rosiglitazone; Streptozocin; Thiazolidinediones; Vasoconstriction; Vasoconstrictor Agents | 2007 |
Ensuring drug safety: lessons from the thiazolidinediones.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hyperglycemia; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2007 |
Insulin resistance and impaired functional vasodilation in obese Zucker rats.
Topics: Animals; Antioxidants; Arachidonic Acid; Arterioles; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Disease Models, Animal; Electric Stimulation; Fatty Acids, Unsaturated; Hydrazines; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Kidney Cortex; Male; Muscle, Skeletal; NADPH Oxidases; Obesity; Oxidative Stress; Rats; Rats, Zucker; Receptors, Thromboxane; Rosiglitazone; Spin Labels; Superoxides; Thiazolidinediones; Thromboxanes; Time Factors; Triglycerides; Vasoconstriction; Vasodilation | 2008 |
Controversy over the cardiovascular effects of thiazolidinediones.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hyperglycemia; Insulin Resistance; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Rosiglitazone; Survival Rate; Thiazolidinediones | 2008 |
Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gene Expression Regulation; Hyperglycemia; Hypoglycemic Agents; Hypothalamus; Insulin; Intracellular Signaling Peptides and Proteins; Leptin; Neuropeptides; Obesity; Orexins; Protein Precursors; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Transcription, Genetic | 2000 |
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000].
Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Topics: Aging; Animals; Cataract; Diabetes Mellitus, Type 2; Glucagon; Hyperglycemia; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Pancreas; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Thirst; Time Factors | 2000 |
Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Liver; Male; Muscle, Skeletal; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.
Topics: 3T3 Cells; Adipose Tissue; Animals; Benzhydryl Compounds; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Epoxy Compounds; Fatty Acids; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Knockout; Nicotinic Acids; Obesity; Receptors, Adrenergic, beta-3; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism.
Topics: Adolescent; Adult; Apolipoproteins B; Body Mass Index; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mutation; Plasminogen Activator Inhibitor 1; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Dose-Response Relationship, Drug; Energy Intake; Energy Metabolism; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Mutant Strains; Organic Chemicals; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |